So that's how it works, says Resverlogix of its lead product
This article was originally published in Scrip
The Canadian biotech company Resverlogix has discovered exactly how its lead cardiovascular product, RVX-208, increases the production of apolipoprotein, in a finding that it says has implications for its entire pipeline.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.